BR112019024412A2 - Usos de composição imunogênica e de vacina compreendendo toxóides de clostridium difficile para tratar e/ou prevenir doença causada por clostridium sp, composiçãoimunogênica e vacina compreendendo toxóides de c. difficile e c. perfringens, processo para preparar a dita vacina, bem como kit de vacinação que compreende a dita composição imunogênica - Google Patents
Usos de composição imunogênica e de vacina compreendendo toxóides de clostridium difficile para tratar e/ou prevenir doença causada por clostridium sp, composiçãoimunogênica e vacina compreendendo toxóides de c. difficile e c. perfringens, processo para preparar a dita vacina, bem como kit de vacinação que compreende a dita composição imunogênica Download PDFInfo
- Publication number
- BR112019024412A2 BR112019024412A2 BR112019024412-3A BR112019024412A BR112019024412A2 BR 112019024412 A2 BR112019024412 A2 BR 112019024412A2 BR 112019024412 A BR112019024412 A BR 112019024412A BR 112019024412 A2 BR112019024412 A2 BR 112019024412A2
- Authority
- BR
- Brazil
- Prior art keywords
- toxoid
- immunogenic composition
- vaccine
- difficile
- fact
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 224
- 229960005486 vaccine Drugs 0.000 title claims abstract description 209
- 230000002163 immunogen Effects 0.000 title claims abstract description 152
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract description 143
- 201000010099 disease Diseases 0.000 title claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 39
- 241000193403 Clostridium Species 0.000 title claims description 30
- 241000193468 Clostridium perfringens Species 0.000 claims abstract description 138
- 241001465754 Metazoa Species 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 34
- 241000282898 Sus scrofa Species 0.000 claims description 54
- 239000000427 antigen Substances 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 241000283690 Bos taurus Species 0.000 claims description 51
- 230000008774 maternal effect Effects 0.000 claims description 39
- 208000015181 infectious disease Diseases 0.000 claims description 37
- 241000193464 Clostridium sp. Species 0.000 claims description 36
- 208000028774 intestinal disease Diseases 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 31
- 230000036039 immunity Effects 0.000 claims description 29
- 238000002255 vaccination Methods 0.000 claims description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 24
- 230000003053 immunization Effects 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 22
- 238000002649 immunization Methods 0.000 claims description 21
- 241000588724 Escherichia coli Species 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 244000005700 microbiome Species 0.000 claims description 14
- 241000606161 Chlamydia Species 0.000 claims description 12
- 241000711484 Transmissible gastroenteritis virus Species 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 241000186581 Clostridium novyi Species 0.000 claims description 11
- 206010012735 Diarrhoea Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 244000309714 Clostridium perfringens type C Species 0.000 claims description 10
- 108010037833 Bacterial Adhesins Proteins 0.000 claims description 9
- 241000702670 Rotavirus Species 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 241000711573 Coronaviridae Species 0.000 claims description 7
- 241000606750 Actinobacillus Species 0.000 claims description 6
- 241000701386 African swine fever virus Species 0.000 claims description 6
- 241000588807 Bordetella Species 0.000 claims description 6
- 241000589968 Borrelia Species 0.000 claims description 6
- 241001148534 Brachyspira Species 0.000 claims description 6
- 241000589562 Brucella Species 0.000 claims description 6
- 241000589876 Campylobacter Species 0.000 claims description 6
- 241000186216 Corynebacterium Species 0.000 claims description 6
- 241000710188 Encephalomyocarditis virus Species 0.000 claims description 6
- 241000588722 Escherichia Species 0.000 claims description 6
- 208000005577 Gastroenteritis Diseases 0.000 claims description 6
- 241000606790 Haemophilus Species 0.000 claims description 6
- 241000589989 Helicobacter Species 0.000 claims description 6
- 208000016604 Lyme disease Diseases 0.000 claims description 6
- 241000125945 Protoparvovirus Species 0.000 claims description 6
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 6
- 210000004877 mucosa Anatomy 0.000 claims description 6
- 230000001850 reproductive effect Effects 0.000 claims description 6
- 230000000241 respiratory effect Effects 0.000 claims description 6
- 201000010740 swine influenza Diseases 0.000 claims description 6
- 210000004876 tela submucosa Anatomy 0.000 claims description 6
- 241000710777 Classical swine fever virus Species 0.000 claims description 5
- 241000186811 Erysipelothrix Species 0.000 claims description 5
- 241000589601 Francisella Species 0.000 claims description 5
- 241000567229 Isospora Species 0.000 claims description 5
- 241001469654 Lawsonia <weevil> Species 0.000 claims description 5
- 241000589248 Legionella Species 0.000 claims description 5
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 5
- 241000606701 Rickettsia Species 0.000 claims description 5
- 241000607142 Salmonella Species 0.000 claims description 5
- 241000191940 Staphylococcus Species 0.000 claims description 5
- 241000194017 Streptococcus Species 0.000 claims description 5
- 241000589886 Treponema Species 0.000 claims description 5
- 241000607598 Vibrio Species 0.000 claims description 5
- 241000194033 Enterococcus Species 0.000 claims description 4
- 241000589902 Leptospira Species 0.000 claims description 4
- 241000607768 Shigella Species 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 241001533384 Circovirus Species 0.000 claims description 3
- 241000186781 Listeria Species 0.000 claims description 3
- 241000186359 Mycobacterium Species 0.000 claims description 3
- 241000202347 Porcine circovirus Species 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 2
- 241000606860 Pasteurella Species 0.000 claims description 2
- 206010066829 Weaning failure Diseases 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 241000960387 Torque teno virus Species 0.000 claims 4
- 241000204031 Mycoplasma Species 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 26
- 230000006806 disease prevention Effects 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 description 103
- 231100000765 toxin Toxicity 0.000 description 103
- 108700012359 toxins Proteins 0.000 description 103
- 238000000034 method Methods 0.000 description 71
- 230000000120 cytopathologic effect Effects 0.000 description 40
- 241000282887 Suidae Species 0.000 description 39
- 239000006228 supernatant Substances 0.000 description 37
- 230000002949 hemolytic effect Effects 0.000 description 29
- 239000003981 vehicle Substances 0.000 description 24
- 230000028993 immune response Effects 0.000 description 20
- 230000006651 lactation Effects 0.000 description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical compound OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 description 17
- 101710124951 Phospholipase C Proteins 0.000 description 16
- 239000002776 alpha toxin Substances 0.000 description 16
- 101710092462 Alpha-hemolysin Proteins 0.000 description 15
- 101710197219 Alpha-toxin Proteins 0.000 description 15
- 230000002779 inactivation Effects 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 230000000890 antigenic effect Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 230000002265 prevention Effects 0.000 description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 12
- 230000001900 immune effect Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000000405 serological effect Effects 0.000 description 12
- 210000003022 colostrum Anatomy 0.000 description 11
- 235000021277 colostrum Nutrition 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 241001112695 Clostridiales Species 0.000 description 8
- 101000963974 Hydrophis stokesii Alpha-elapitoxin-Ast2b Proteins 0.000 description 8
- 101000964025 Naja naja Long neurotoxin 3 Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 206010022678 Intestinal infections Diseases 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 230000000415 inactivating effect Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 244000144972 livestock Species 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241001112696 Clostridia Species 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 5
- -1 TWEENG Chemical compound 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 101710146739 Enterotoxin Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000000147 enterotoxin Substances 0.000 description 4
- 231100000655 enterotoxin Toxicity 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101710110820 Pesticin receptor Proteins 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229940024545 aluminum hydroxide Drugs 0.000 description 3
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 3
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002095 exotoxin Substances 0.000 description 3
- 231100000776 exotoxin Toxicity 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010048612 Hydrothorax Diseases 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 101710182532 Toxin a Proteins 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- OTIXUSNHAKOJBX-UHFFFAOYSA-N 1-(aziridin-1-yl)ethanone Chemical compound CC(=O)N1CC1 OTIXUSNHAKOJBX-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000924311 Clostridium novyi B Species 0.000 description 1
- 101000998837 Clostridium perfringens (strain 13 / Type A) Hyaluronoglucosaminidase Proteins 0.000 description 1
- 241001522882 Clostridium perfringens A Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000498886 Collimonas arenae Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 241000776471 DPANN group Species 0.000 description 1
- 101710121036 Delta-hemolysin Proteins 0.000 description 1
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108050004280 Epsilon toxin Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010067993 Mucosal necrosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000800763 Naja pallida Short neurotoxin 1 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710103914 Perfringolysin O Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 231100001102 clostridial toxin Toxicity 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 244000000021 enteric pathogen Species 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001537 mesocolon Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382358 | 2017-06-09 | ||
| EP17382358.4 | 2017-06-09 | ||
| PCT/EP2018/065025 WO2018224595A1 (en) | 2017-06-09 | 2018-06-07 | Vaccine comprising clostridium toxoids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019024412A2 true BR112019024412A2 (pt) | 2020-07-14 |
Family
ID=59078007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019024412-3A BR112019024412A2 (pt) | 2017-06-09 | 2018-06-07 | Usos de composição imunogênica e de vacina compreendendo toxóides de clostridium difficile para tratar e/ou prevenir doença causada por clostridium sp, composiçãoimunogênica e vacina compreendendo toxóides de c. difficile e c. perfringens, processo para preparar a dita vacina, bem como kit de vacinação que compreende a dita composição imunogênica |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11154605B2 (enExample) |
| EP (1) | EP3634480A1 (enExample) |
| JP (2) | JP7349366B2 (enExample) |
| BR (1) | BR112019024412A2 (enExample) |
| CA (1) | CA3064357A1 (enExample) |
| MX (1) | MX388528B (enExample) |
| WO (1) | WO2018224595A1 (enExample) |
| ZA (1) | ZA201907715B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202509058A (zh) * | 2023-08-24 | 2025-03-01 | 法商西華動物藥品股份有限公司 | 抗豬感染之多價疫苗 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY149604A (en) | 2005-04-18 | 2013-09-13 | Schering Plough Ltd | C.perfringens alpha toxoid vaccine |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| US20160045586A1 (en) | 2013-03-15 | 2016-02-18 | Sanofi Pasteur, Inc. | Toxoid, Compositions and Related Methods |
-
2018
- 2018-06-07 JP JP2019564131A patent/JP7349366B2/ja active Active
- 2018-06-07 WO PCT/EP2018/065025 patent/WO2018224595A1/en not_active Ceased
- 2018-06-07 EP EP18731386.1A patent/EP3634480A1/en active Pending
- 2018-06-07 BR BR112019024412-3A patent/BR112019024412A2/pt unknown
- 2018-06-07 US US16/620,846 patent/US11154605B2/en active Active
- 2018-06-07 MX MX2019013779A patent/MX388528B/es unknown
- 2018-06-07 CA CA3064357A patent/CA3064357A1/en active Pending
-
2019
- 2019-11-21 ZA ZA2019/07715A patent/ZA201907715B/en unknown
-
2023
- 2023-05-09 JP JP2023076996A patent/JP2023113631A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX388528B (es) | 2025-03-20 |
| ZA201907715B (en) | 2024-09-25 |
| WO2018224595A1 (en) | 2018-12-13 |
| CA3064357A1 (en) | 2018-12-13 |
| JP2020522471A (ja) | 2020-07-30 |
| MX2019013779A (es) | 2020-01-13 |
| US20200188500A1 (en) | 2020-06-18 |
| JP7349366B2 (ja) | 2023-09-22 |
| US11154605B2 (en) | 2021-10-26 |
| EP3634480A1 (en) | 2020-04-15 |
| JP2023113631A (ja) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2903120T3 (es) | Composición y procedimiento para el tratamiento y la prevención de infecciones por enterobacterias | |
| ES2905302T3 (es) | Vacuna de Mycoplasma hyopneumoniae | |
| BRPI0608439B1 (pt) | vacinas combinadas compreendendo lawsonia intracellularis, salmonella spp e erysipelothrix rhusiopathiae, e kits | |
| US10279031B2 (en) | Composition comprising antigens and a mucosal adjuvant and a method for using | |
| CA2606180A1 (en) | C. perfringens alpha toxoid vaccine | |
| AU2015310932B2 (en) | Attenuated bovine coronavirus and related vaccines | |
| JP2008169207A (ja) | ワクチン投与方法 | |
| BR112020011593A2 (pt) | Uma vacina para proteção contra streptococcus suis | |
| US11696944B2 (en) | Vaccine for protection against Streptococcus suis | |
| US10751403B2 (en) | Vaccine for protection against Streptococcus suis | |
| JP2023113631A (ja) | クロストリジウム類毒素を含むワクチン | |
| BR112020002004A2 (pt) | vacina para proteção contra streptococcus suis | |
| CA2866199A1 (en) | Novel veterinary vaccine | |
| BR112021002900A2 (pt) | vacina de combinação | |
| JP7728784B2 (ja) | ストレプトコッカス・スイス血清型９、配列型１６に対する防御のためのワクチン | |
| BR112020011831A2 (pt) | vacina para proteção contra streptococcus suis | |
| CN114901293B (zh) | 用于预防或治疗幼小的哺乳动物得与黏膜相关的传染性疾病的血清组成物的制造方法、通过该方法制造的血清组成物及其用途 | |
| RU2777065C1 (ru) | Комбинированная вакцина | |
| WO2025040792A1 (en) | Multivalent vaccine against swine infections | |
| Reynaud et al. | Evaluation of An Associated Inactivated Vaccine Against Neonatal Diarrhoeas Caused by Colibacilli, Rotavirus and Coronavirus | |
| Bowersock | Induction of pulmonary immunity to pasteurella haemolytica in cattle by stimulation of the gut-associated lymphatic tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |